{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:22:58Z","timestamp":1789608178826,"version":"build-2803163510"},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Based upon the development of highly effective therapies such as immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies that target plasma cell biology, a dramatic improvement in overall survival has been observed for most patients with multiple myeloma (MM) over the past 2 decades. Although it is now commonplace for many patients with myeloma to live in excess of 10 years after diagnosis, unfortunately a large subset of patients continues to experience an aggressive disease course marked by substantial morbidity and early mortality. Many clinical biomarkers and staging systems in use today can help with prognostication, but accurate risk assessment can be difficult due to the presence of many different biomarkers with variable prognostic value. Furthermore, with the implementation of novel therapies and unprecedented rates of deep and durable responses, it is becoming apparent that risk assessment is best envisioned as a dynamic process that requires ongoing reevaluation. As risk and response-adapted approaches are becoming more commonplace, it is essential that clinicians understand the biological and prognostic implications of clinical, genomic, and response-based biomarkers in order to promote management strategies that will help improve both survival and quality of life for patients across the risk spectrum.<\/jats:p>","DOI":"10.1182\/hematology.2022000347","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T11:10:56Z","timestamp":1670584256000},"page":"349-355","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["High or low? Assessing disease risk in multiple myeloma"],"prefix":"10.1182","volume":"2022","author":[{"given":"Timothy Martin","family":"Schmidt","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Palliative Care, University of Wisconsin, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"2","key":"2022120916083675900_hem2022000347C1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"15","key":"2022120916083675900_hem2022000347C2","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"2022120916083675900_hem2022000347C3","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022120916083675900_hem2022000347C4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"2022120916083675900_hem2022000347C5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2022120916083675900_hem2022000347C6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.1996.d01-2939.x","article-title":"Multiple myeloma: almost all patients are cytogenetically abnormal","volume":"94","author":"Zandecki","year":"1996","journal-title":"Br J Haematol"},{"issue":"2","key":"2022120916083675900_hem2022000347C7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood.V71.2.453.453","article-title":"Plasma cell karyotype in multiple myeloma","volume":"71","author":"Gould","year":"1988","journal-title":"Blood"},{"issue":"6","key":"2022120916083675900_hem2022000347C8","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2022120916083675900_hem2022000347C9","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2022120916083675900_hem2022000347C10","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"2022120916083675900_hem2022000347C11","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1038\/bcj.2015.91","article-title":"Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma","volume":"5","author":"Vu","year":"2015","journal-title":"Blood Cancer J"},{"issue":"8","key":"2022120916083675900_hem2022000347C12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-020-00353-8","article-title":"Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma","volume":"10","author":"Paquin","year":"2020","journal-title":"Blood Cancer J"},{"issue":"5","key":"2022120916083675900_hem2022000347C13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood-2014-07-584268","article-title":"Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations","volume":"125","author":"Pawlyn","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2022120916083675900_hem2022000347C14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-020-0285-6","article-title":"Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis","volume":"10","author":"Baril\u00e0","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2022120916083675900_hem2022000347C15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/leu.2017.204","article-title":"Natural history of t(11;14) multiple myeloma","volume":"32","author":"Lakshman","year":"2018","journal-title":"Leukemia"},{"issue":"22","key":"2022120916083675900_hem2022000347C16","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2022120916083675900_hem2022000347C17","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2022120916083675900_hem2022000347C18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"10","key":"2022120916083675900_hem2022000347C19","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","article-title":"Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma\u2014a meta-analysis of 2,596 trial patients","volume":"106","author":"Weinhold","year":"2021","journal-title":"Haematologica"},{"issue":"suppl 2","key":"2022120916083675900_hem2022000347C20","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S2152-2650(21)02126-1","article-title":"OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial","volume":"21","author":"Kapoor","year":"2021","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"issue":"4","key":"2022120916083675900_hem2022000347C21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2022120916083675900_hem2022000347C22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-137060","article-title":"Impact of gain and amplification of 1q in newly diagnosed multiple myeloma patients receiving carfilzomib-based treatment in the forte trial","volume":"136","author":"D'Agostino","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2022120916083675900_hem2022000347C23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"key":"2022120916083675900_hem2022000347C24","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project [published online ahead of print 23 May 2022]","author":"D'Agostino","journal-title":"J Clin Oncol"},{"issue":"21","key":"2022120916083675900_hem2022000347C25","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022120916083675900_hem2022000347C26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"issue":"24","key":"2022120916083675900_hem2022000347C27","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-20-2283","article-title":"Implications of MYC rearrangements in newly diagnosed multiple myeloma","volume":"26","author":"Abdallah","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2022120916083675900_hem2022000347C28","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1158\/1078-0432.CCR-21-0005","article-title":"The prognostic role of MYC structural variants identified by NGS and FISH in multiple myeloma","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2022120916083675900_hem2022000347C29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"47","key":"2022120916083675900_hem2022000347C30","doi-asserted-by":"crossref","first-page":"eabg9551","DOI":"10.1126\/sciadv.abg9551","article-title":"Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications","volume":"7","author":"Bhalla","year":"2021","journal-title":"Sci Adv"},{"issue":"9","key":"2022120916083675900_hem2022000347C31","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.leu.2404832","article-title":"Heterogeneity of t(4;14) in multiple myeloma: long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials","volume":"21","author":"Moreau","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"2022120916083675900_hem2022000347C32","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2022120916083675900_hem2022000347C33","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","article-title":"Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?","volume":"117","author":"Avet-Loiseau","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2022120916083675900_hem2022000347C34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.clml.2017.06.020","article-title":"Prognostic validation of SKY92 and its combination with ISS in an independent cohort of patients with multiple myeloma","volume":"17","author":"van Beers","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022120916083675900_hem2022000347C35","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"3","key":"2022120916083675900_hem2022000347C36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"2022120916083675900_hem2022000347C37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.25709","article-title":"Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells","volume":"95","author":"Gonsalves","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"2022120916083675900_hem2022000347C38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17118","article-title":"The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma","volume":"193","author":"Galieni","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2022120916083675900_hem2022000347C39","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"2022120916083675900_hem2022000347C40","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2021-149112","article-title":"Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)","volume":"138","author":"Maura","year":"2021","journal-title":"Blood"},{"issue":"23","key":"2022120916083675900_hem2022000347C41","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"2022120916083675900_hem2022000347C42","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2022120916083675900_hem2022000347C43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"issue":"19","key":"2022120916083675900_hem2022000347C44","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood.2021012319","article-title":"Validation of the International Myeloma Working Group standard response criteria in the PETHEMA\/GEM2012MENOS65 study: are these times of change?","volume":"138","author":"Jim\u00e9nez-Ubieto","year":"2021","journal-title":"Blood"},{"issue":"14","key":"2022120916083675900_hem2022000347C45","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","article-title":"Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma","volume":"4","author":"Martinez-Lopez","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2022120916083675900_hem2022000347C46","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"2022120916083675900_hem2022000347C47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2022120916083675900_hem2022000347C48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41408-019-0176-x","article-title":"Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature","volume":"9","author":"Rodr\u00edguez-Otero","year":"2019","journal-title":"Blood Cancer J"},{"key":"2022120916083675900_hem2022000347C49","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma [published online ahead of print 13 December 2021]","author":"Costa","journal-title":"J Clin Oncol"},{"issue":"9","key":"2022120916083675900_hem2022000347C50","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2022120916083675900_hem2022000347C51","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"2022120916083675900_hem2022000347C52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.26391","article-title":"Prognostic significance of acquired 1q22 gain in multiple myeloma","volume":"97","author":"Audil","year":"2022","journal-title":"Am J Hematol"},{"issue":"13","key":"2022120916083675900_hem2022000347C53","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/bloodadvances.2018028530","article-title":"Impact of acquired del(17p) in multiple myeloma","volume":"3","author":"Lakshman","year":"2019","journal-title":"Blood Adv"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/349\/2021852\/349schmidt.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/349\/2021852\/349schmidt.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T11:11:26Z","timestamp":1670584286000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/349\/493555\/High-or-low-Assessing-disease-risk-in-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000347","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}